GlassScriptPhysician profile
Laine E Keahey
NPI 1144244807
$1,963.09
in general payments reported to CMS, 2019-2025
25 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $189 · 2021: $513 · 2022: $551 · 2023: $176 · 2024: $96.37 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Consulting Fee: $8.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.83 |
| Consulting Fee | $8.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $447.70 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $240.97 | 2019-2022 | |
| Genzyme Corporation | $220.93 | 2019-2025 | |
| Optinose US, INC. | $191.98 | 2019-2022 | |
| Pfizer INC. | $120.64 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.92 | 2021-2025 | Cuvitru |
| Kaleo, INC. | $88.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $85.22 | 2019-2025 | Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $76.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $63.65 | 2019-2021 | |
| Grifols USA, LLC | $49.47 | 2021-2022 | |
| Pharming Healthcare, INC. | $41.80 | 2022-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $29.10 | 2025 | Neffy |
| Genentech USA, INC. | $25.55 | 2024 | Xolair |
| Lilly USA, LLC | $24.07 | 2025 | Ebglyss |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $20.00 | 2022 | |
| Amgen INC. | $18.71 | 2025 | Tezspire |
| Incyte Corporation | $17.20 | 2021 | |
| Biocryst US Sales Co., LLC | $17.10 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.79 | 2021 | |
| Hikma Pharmaceuticals USA | $15.79 | 2021 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Uswm, LLC | $12.57 | 2021 | |
| Adma Biomanufacturing LLC | $8.07 | 2025 | |
| Cycle Pharmaceuticals INC | $7.32 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laine Keahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.